- Everything on track.
- cash spending inline and should easily get us through CY25 as mentioned.
- no issues with first 9 patient test.
-recruitment for ATL1102 looking to be achieved by end of this qtr and results in by end of year.
-toxicology results mid year
Worth holding a parcel till end of year results as positive outcome I assume most on here would agree this goes up 10x or more from current price levels.
But as always in these studies the outcome is never certain.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
-0.001(1.32%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.5¢ | $18.25K | 237.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18038 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 120000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
-0.001 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| 8.0¢ | 8.0¢ | 7.5¢ | 59548 | ||
| Last updated 15.20pm 10/05/2024 ? | |||||
| PER (ASX) Chart |